Skip to contentpdufa.bio

LIPFENDRA (enlicitide decanoate): FDA NDA 220848

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 220848 is the FDA application for LIPFENDRA (enlicitide decanoate). The FDA's Orange Book lists the applicant of record as MERCK SHARP AND DOHME LLC and the first approval on it as Jul 15, 2026. Code name used in development: MK-0616. Owner today: Merck & Co., Inc. (NYSE: MRK).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220848 · Orange Book NDA 220848

Names for this drug

Brand name (FDA)LIPFENDRA
Orange Book trade name: LIPFENDRA
Active ingredient (FDA)ENLICITIDE DECANOATE
Code nameMK-0616
Source: Merck 10-K, Feb 25, 2025
“MK-0616 (enlicitide decanoate)”

Who holds the application

FDA applicant of recordMERCK SHARP AND DOHME LLC
FDA Orange Book data files as of Nov 13, 2026
Owner todayMerck & Co., Inc. (MRK)
Source: Merck press release, Jul 16, 2026
“Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced”

Products on NDA 220848 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001LIPFENDRATABLET;ORALEQ 20MG BASEJul 15, 2026

FDA decisions we track for this drug

Lipfendra (enlicitide decanoate)MRK · Decided

Drug page: /drug/lipfendra

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.